Showing all 3 results
Lipid Nanoparticle (LNP)
The development of mRNA-based vaccines against COVID-19 have proven that lipid nanoparticles (LNPs) are a suitable delivery form. Lipid nanoparticles encapsulate and protect the fragile active ingredient allowing it to transfer to the target cells in the human body.
Solid lipid nanoparticles (SLNs) represent a fairly new colloidal drug delivery system that is composed of physiological lipids that remain at a solid state at both room temperature and body temperature. The particles range in size from 50-1000 nm. Lipid-based nanoparticle (LBNP) systems are one of the most promising colloidal carriers.
There are new, promising developments in medicine that make pharmaceuticals and their active ingredients increasingly complex challenges. For example, Oligonucleotides are very susceptible to degradation in the human body. LNPs have proven to be able to form a stable basis for the administration of many active ingredients like mRNA, RNA, siRNA, and DNA-based APIs. A new field of research is focused on APIs (active pharmaceutical ingredient) and optimization of delivery to the target cells.
Systems for production are called IJM (impingement jet mixing) skids. These skids are designed and optimized to meet our customer’s specific needs. Our systems are equipt with all the necessary interfaces to enable customers to integrate their own PLC (programmable logic controller) systems.
ICON Scientific, Inc
